|
|
Post by careful2invest on Dec 8, 2017 6:44:25 GMT -5
I just received a large envelope from Sanofi.
Before I opened it, after reading Sanofi as the sender, you can bet that my imagination was going...
But in it was only information and promotional material for Tojeo and Lantus.
I am not diabetic and am unsure why my name and address is on a Sanofi mailing list.
I thought this was strange!
Did anyone else get one of these?
GLTA!
|
|
|
|
Post by sportsrancho on Dec 8, 2017 7:04:46 GMT -5
Another SNY snafu :-)
|
|
|
|
Post by mnkdfann on Dec 8, 2017 10:34:25 GMT -5
I just received a large envelope from Sanofi. Before I opened it, after reading Sanofi as the sender, you can bet that my imagination was going... But in it was only information and promotional material for Tojeo and Lantus. I am not diabetic and am unsure why my name and address is on a Sanofi mailing list. I thought this was strange! Did anyone else get one of these? GLTA! Perhaps the box service 'Mallomars Monthly' sold its mailing list? Wait, that might only apply to Spiro ... |
|
|
|
Post by mnholdem on Dec 12, 2017 8:54:51 GMT -5
Sanofi Investors Crave for a Large Acquisition, Drug News
Published: Dec 12, 2017
PARIS (Reuters) - Sanofi (SASY.PA) still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.
The French drugmaker holds an “innovation day” on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine.
Already irked by the lack of a large acquisition since Olivier Brandicourt was appointed as chief executive in 2015, some investors are losing patience that has been stretched for months.
Source: www.reuters.com/article/us-sanofi-strategy-investors/sanofi-investors-hungry-for-drug-progress-and-deal-news-idUSKBN1E61C7
|
|
